You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK)與美國上市藥企Alimera訂立獨家許可協議
格隆匯 04-14 23:57

格隆匯 4 月 14日丨歐康維視生物-B(01477.HK)宣佈,於2021年4月14日,公司全資附屬香港歐康維視與Alimera(一間普通股股份以股份代號"ALIM"於納斯達克交易的公司)已訂立獨家許可協議,據此,Alimera同意就於經許可地區的許可產品向集團授出許可權。有鑑於此,香港歐康維視同意向Alimera支付預付款1000萬美元及於達致獨家許可協議所協定的許可產品某一銷售淨額後支付金額最高為8900萬美元的總潛在銷售里程碑付款。

據悉,許可產品(即190微克氟輕鬆玻璃體內植入劑(0.19毫克))已獲得美國食品藥品監督管理局的監管批准,且以商號"ILUVIEN®"上市。許可產品通過於眼部連續使用最多36個月的微量非專有皮質類固醇類固醇氟輕鬆酮(FAc)治療糖尿病性黃斑水腫(DME)。

經許可地區包括中國、香港和澳門、台灣地區、韓國、汶萊、柬埔寨、東帝汶、印尼、老撾、馬來西亞、緬甸、菲律賓、新加坡、泰國及越南。

於同日,公司與Alimera訂立股份購買協議,據此,Alimera已同意發行及出售,而公司已同意根據股份購買協議的條款及條件收購1,144,945股Alimera股份,總代價約為1000萬美元。於股份購買協議項下的交易完成後,公司持有Alimera已發行及發行在外普通股股份總數約16.6%。

鑑於集團與Alimera建立的戰略合作關係,於同日,公司與Alimera訂立認股權證認購協議,據此,公司同意向Alimera發行100萬份認股權證,該等認股權證賦予權利按認購價每股認股權證股份23.88港元(可予調整)認購合共100萬股認股權證股份,名義代價為1.00港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account